2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2006
Neurobiology of anxiety disorders and implications for treatment.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Annals Of Global Health 2006, 73: 941-9. PMID: 17195879.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-traumatic stress disorderCognitive behavioral therapyFear conditioningUnconditioned stimulusAnxiety disordersPartial NMDA agonistFear inhibitionFear extinctionTraumatic memoriesFear circuitryFear responsesPavlovian conditioningBehavioral therapyStress disorderSpecific phobiaNew learningAmygdala pathwayD-cycloserineAnti-anxiety treatmentPanic disorderPreliminary evidenceStimuliMemoryN-methyl-D-aspartate antagonistsNeurobiology